CD47 and neoplasm: We next investigated whether CD47 blockade was eliciting the desired effect on different APC subsets, type I and type II conventional dendritic cells (cDC1 and cDC2), plasmacytoid dendritic cells (pDCs), and macrophages using recombinant B16-F10 tumor cells engineered to express zsGreen and the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) epitope GP33.